rapid-b platform

Aperture Bio's RAPID-B platform technology is the first commercial quantitative microbiological platform to be applied to infectious disease testing. Based on nextgen flow cytometric principles coupled to high-throughput automation to meet the demands of the 21st century clinical microbiology laboratory, the platform aims to redefine the approach to suspected bacterial infections.


Fluidics and laser optimization coupled to Aperture's proprietary sample chemistry allow for robust and accurate gating protocols that enable highly accurate live bacterial cell enumeration in minutes...This is the foundation of Aperture Bio's clinical assays. By accurately enumerating live bacteria Aperture is able to assess changes in original bacterial populations in the presence of antibiotics over a short time period. This approach uses the foundational definition of resistance and susceptibility, the inability or ability to divide in the presence of a compound, to define the bacteria's phenotype.


The application of Aperture's technology to samples suspected of containing pathogenic bacteria has the ability to transform the way these patients are diagnosed and treated. For example, the rapid nature and high accuracy of our UTI assay when applied to uncomplicated, outpatient UTI patients can improve outcomes by providing treating physicians fast confirmation of UTI microbiology AND direct appropriate therapy for these patients. Currently, no technology exists to provide this information...information that is critical in the context of dramatically rising antibiotic resistance rates.


The application of the Aperture Bio technology to suspected bloodstream infections also has the potential to dramatically change the way these patients are approached. Early data suggests the empiriSTAT Blood assay can detect the presence of bacteria in blood samples in half the time of current carbon dioxide-sensing platforms. Coupled with Aperture's Antibiotic Predictive Profile the empiriSTAT Blood assay aims to provide important actionable data to treating physicians to reduce mortality and improve outcomes by getting efficacious antimicrobials on board sooner.

image1

Video

Lean more about our technology in this video

flow-cytometry

Highly accurate bacterial enumeration is the key to Aperture Bio's technology. The application of the Aperture Bio chemistry and platform architecture enable a rapid bacterial assessment in minutes directly out of the sample. Applying this to suspected UTI specimens allows the system to confirm or rule-out a UTI in minutes. Applying the high negative predictive value of the test will dramatically reduce antibiotic use.


While bacterial enumeration is necessary for diagnosing a clinical UTI the exceptional accuracy of Aperture's approach enables live-cell bacterial enumeration to be applied to phenotypic antibiotic profiling of samples containing bacterial populations. This phenotypic approach is the simplest measure of an antibiotic's effectiveness...Does the bacteria present in the sample have the ability to divide and expand in the presence of a specific antibiotic? This approach is much more comprehensive than any genetic variant assay and provides a more confident result to physicians. 


ABOUT:  Flow Cytometry is a technique used to detect and measure physical and chemical characteristics of a population of cells or particles in a sample containing cells or particles is suspended in a fluid 

and injected into the flow cytometer instrument. The sample is focused to ideally flow one cell at a time through a laser beam and the light scattered is characteristic to the cells and their components. Cells are often labeled with fluorescent markers so that light is first absorbed and then emitted in a band of wavelengths. Tens of thousands of cells can be quickly examined,and the data gathered are processed by a computer

image2

patents & FDA approval pending